



Global Biologics Systems Company



Executive Summary

SENTRIX operates a biologics system built on UC-MSC conditioned media a cell free, full secretome containing the complete regenerative network produced by umbilical cord mesenchymal stem cells. This is a biologics system, not a cosmetic isolate. SENTRIX holds a looked valuation floor of £82 million and is positioned for global expansion and a 36 month IPO pathway.



REFERENCE BIOLOGIC PAYLOAD



£82M
VALUATION FLOOR

36 MONTHS
IPO PATHWAY

SLIDE 3

The Biologic Payload

UC-MSC CM contains the complete regenerative network




The cell is only the manufacturing unit. The payload is the secretome.

REFERENCE: FULL SECRETOME

Why Cell Free Biologics Win


Superior Safety



- ✓ No pulmonary trapping
- ✓ No microvascular obstruction
- ✓ No immune activation
- ✓ No cell-death toxicity
- ✓ No theoretical tumorigenicity

Superior Consistency

Cells are variable. CM is standardised.



Trehalose stabilisation preserves proteins, microRNAs, vesicles, lipid mediators, and peptides.

Superior Scalability

Cell therapy does not scale. Cell free biologics do.

CM is manufacturable, stable, shippable, batch, consistent, and globally scalable.




SLIDE 5

SENTRIX Biologics Manufacturing



King Stem Cell produces UC-MSC CM under:




— This creates a premium full secretome unmatched in the market. —

REFERENCE: KING STEM CELL MANUFACTURING

Subscription Platform

-  1 Cosmetic classified, biologic adjacent delivery
-  2 Continuous product cadence every 10 weeks
-  3 High retention and recurring revenue
-  4 Global fulfilment across the United States, United Kingdom, European Union, and Asia
-  5 Scalable biologic-adjacent architecture



SLIDE 7

Global IP Fortress

SENTRIX holds:



UNITED STATES



SENTRIX — Classes 9, 35, 36, 42, 45



KING STEM CELL — Classes 1, 3, 5, 44



UNITED KINGDOM



VITACEREBRUM — Class 5



KING STEM CELL — Class 44

— This creates a multi jurisdiction biologics IP fortress. —

REFERENCE: IP FORTRESS

Market Positioning


1 Peptides

Single-message
cosmetic signals.
No cargo.




2 Exosome Isolates

Narrow fragments.
No cytokines. No growth factors.
No microRNAs. No lipid mediators.



3 UC-MSC CM

Full biologic network.
Multi pathway regenerative signalling.
Stable. Scalable. Clinician grade.



SENTRIX owns the biologic category.

SLIDE 9


King Stem Cell vs. Market UC-MSC





MARKET UC-MSC

21% oxygen

-  FBS
-  Animal inputs
-  DMSO



Increased oxidative stress and reduced purity



VS





KING STEM CELL UC-MSC

Tri-gas low oxygen

-  Xeno free
-  FBS free
-  DMSO free



Preserved stemness, reduced senescence,
and a cleaner biologic signal



Same cell type. Completely different biology.

SLIDE 10

The Two Biologic Products


UC-MSCs

Finest grade stem cells produced under tri gas, low oxygen, xeno free, FBS free, and DMSO free conditions.



UC-MSC CM

Full secretome conditioned media in 5 mL and 10 mL formats. Trehalose-stabilised. Clinician grade. Subscription ready.



REFERENCE: FULL SECRETOME CM

SENTRIX Capital Architecture

TWO PARALLEL CAPITAL PATHWAYS



PATHWAY 1

\$50M EQUITY RAISE



Biologics scale



Delivery architecture expansion



Subscription growth



Global IP consolidation

PATHWAY 2

IP-BACKED CAPITAL ROUTE

Activates if equity capital does not close



SENTRIX is a system company and continues forward under either pathway.

SLIDE 12

Use of Funds



BIOLOGICS SCALE-UP

UC-MSC CM production expansion, lyophilisation capacity, purification suites, quality systems, and global export readiness.



DELIVERY ARCHITECTURE EXPANSION

Microneedling, sublingual soft press, and dissolving strip lines.



SUBSCRIPTION PLATFORM GROWTH

Cadence expansion, fulfilment, customer acquisition, retention systems, and analytics.



IP AND GOVERNANCE

Cross border trademark expansion, SENTRIX governance systems, biologics chain of custody, and regulatory positioning.




WORKING CAPITAL AND TEAM

Operations, manufacturing staff, platform engineering, and capital markets readiness.


REFERENCE: USE OF FUNDS

IP Backed Capital Pathway



SENTRIX raises capital against **IP** if equity does not close.

Unstoppable System Company



System companies do not stop.
SENTRIX continues forward under any capital scenario.

SLIDE 15

Capital Markets Message

36 month IPO roadmap

\$50M
CAPITAL RAISE



Biologics manufacturing



Delivery architecture



Subscription operations



IPO execution

SENTRIX



If equity capital does not close,
SENTRIX activates its IP backed
financing pathway.



Biologics engine



IP fortress



Subscription
platform

The biologics engine, IP fortress, and subscription platform ensure uninterrupted forward motion.


THE TRAIN DOES NOT STOP.



REFERENCE: CAPITAL MESSAGE


SLIDE 16

Revenue Architecture



REFERENCE: REVENUE ARCHITECTURE

Investment Thesis



SENTRIX outpaces therapeutic programs with a parallel architecture that reaches consumers now.

SENTRIX Valuation Narrative

Biologics IP
portfolio



Full secretome
manufacturing capability



Subscription
platform



Multi product
architecture



System company
positioning



Capital pathways: equity,
IP backed credit, and
family office anchors



£82M
LOCKED VALUATION FLOOR

IPO Roadmap



PHASE 1

Platform Acceleration



Biologics scale



Subscription deployment

PHASE 2

Institutional Capital



Institutional capital



Global expansion



Manufacturing scale

PHASE 3

Pre IPO structuring and Nasdaq execution



Governance



Audit/readiness documents



Market infrastructure



Nasdaq execution




36-MONTH TIMELINE

36
MONTHS



REFERENCE: IPO ROADMAP

SENTRIX is commercialising a biologic adjacent delivery platform that reaches market years ahead of therapeutic rejuvenation technologies.



 **MULTI YEAR REGULATORY ADVANTAGE**

 **SCALABLE BIOLOGIC-ADJACENT PLATFORM**

 **CAPITAL EFFICIENT GLOBAL EXPANSION**



SLIDE 21

Contact



Global Biologics Systems Company

Pasadena research and development infrastructure




Data room available upon request

REFERENCE: CONTACT |


SLIDE 22

Capital Architecture Integration Summary




The capital architecture section replaces the previous capital markets slides and now reflects SENTRIX as a dual track capital engine with unstoppable forward motion.


Biologic Engine Overview



Delivery Architecture Overview



System Company Identity



SENTRIX Forward Motion

SENTRIX continues under any capital scenario.

